SHLP2 and SHLP6 — The Expanding Mitochondrial-Derived Peptide Family

How the SHLP family was discovered

Pinchas Cohen's group at USC Davis School of Gerontology identified the SHLP family in 2016 through a bioinformatics approach — scanning the mitochondrial 16S rRNA region for previously unidentified open reading frames that could encode short peptides. All six SHLPs (SHLP1-6) are encoded in overlapping or adjacent reading frames in the same 16S rRNA region that encodes Humanin, explaining why they share structural similarities but have distinct amino acid sequences and receptor binding properties. The discovery reinforced the emerging concept of the mitochondrial genome as a source of regulatory peptide signals beyond its canonical role in encoding ETC components.

SHLP2: cytoprotection with anabolic-sparing properties

SHLP2 shares Humanin's primary receptor systems (FPR2/ALX and gp130) but with a different binding affinity profile that produces overlapping but distinct downstream effects. Like Humanin, SHLP2 activates STAT3 and PI3K/Akt anti-apoptotic pathways to protect cells from stress-induced programmed death. Its characterization in retinal pigment epithelium cells showed significant protection against oxidative stress-induced apoptosis — relevant to age-related macular degeneration research. A metabolic phenotyping study in high-fat-diet obese mice showed SHLP2 administration significantly reduced adipose tissue accumulation while preserving lean mass — an anabolic-sparing effect not as prominently documented for Humanin. SHLP2 levels, like all MDPs, decline with age and in metabolic disease states, suggesting a physiological role in the body's own response to metabolic stress that erodes with aging. See the SHLP2 research profile.

SHLP6: a dual-edged compound with unique properties

SHLP6 presents a research profile that distinguishes it from all other MDPs: it demonstrates pro-apoptotic effects in cancer cell lines while retaining cytoprotective effects in normal cells. This dual property — eliminating abnormal cells while protecting normal ones — has attracted attention from longevity-oncology overlap researchers who see potential in compounds that selectively eliminate damaged, dysfunctional, or cancerous cells while preserving healthy tissue. The mechanistic basis of SHLP6's differential effects is under active investigation. Current evidence points toward differences in mitochondrial membrane potential between cancer cells and normal cells — cancer cells characteristically have depolarized mitochondria that alter the intracellular distribution and effect of compounds that interact with mitochondrial membrane components. SHLP6 likely exploits these membrane differences, similar to the way FOXO4-DRI exploits the FOXO4 overexpression difference between senescent and healthy cells. See the SHLP6 research profile.

Integrating SHLPs into the mitochondrial research stack

The existing Mito Stack (SS-31 + MOTS-c + NAD+) addresses mitochondrial membrane repair, biogenesis signaling, and coenzyme substrate respectively. Adding Humanin and SHLP2 extends the stack into cytoprotective coverage — protecting existing mitochondria-containing cells from apoptosis during the repair and biogenesis phases. SHLP2 and Humanin can be used on alternating days (rather than simultaneously) to maintain cytoprotective signaling without receptor saturation. For advanced longevity researchers interested in SHLP6's dual properties, it is used on a more conservative and monitored protocol given its pro-apoptotic profile in some cell types. See the MDP Family Research Guide for the broader mitochondrial context.

Research references

• Cobb LJ, et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis — Aging
• Reynolds JC, et al. (2021). MOTS-c is an exercise-induced mitochondrial encoded regulator — Nature Communications